Compare ALLO & WNEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALLO | WNEB |
|---|---|---|
| Founded | 2017 | 1853 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 259.2M |
| IPO Year | 2018 | N/A |
| Metric | ALLO | WNEB |
|---|---|---|
| Price | $1.38 | $12.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 2 |
| Target Price | $8.67 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 2.5M | 52.9K |
| Earning Date | 11-06-2025 | 01-27-2026 |
| Dividend Yield | N/A | ★ 2.17% |
| EPS Growth | N/A | ★ 27.15 |
| EPS | N/A | ★ 0.66 |
| Revenue | N/A | ★ $79,080,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $100.00 | $7.48 |
| P/E Ratio | ★ N/A | $19.51 |
| Revenue Growth | N/A | ★ 9.08 |
| 52 Week Low | $0.86 | $7.63 |
| 52 Week High | $3.78 | $13.95 |
| Indicator | ALLO | WNEB |
|---|---|---|
| Relative Strength Index (RSI) | 49.50 | 53.92 |
| Support Level | $1.32 | $13.20 |
| Resistance Level | $1.52 | $13.51 |
| Average True Range (ATR) | 0.10 | 0.34 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 28.57 | 14.29 |
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.